Intravascular introduction
Magnetic navigation
Stroma penetration
Triggered release
Monodisperse 120 nm carriers are administered parenterally, remaining immunologically quiescent while circulating within physiological hydrodynamic shear parameters.
External tri-axial electromagnetic arrays generate focused field gradients, counteracting capillary drag forces to steer carriers toward targeted solid tumour margins.
Coordinated rotational field frequencies induce nanomechanical locomotion, actively transporting carriers past dense interstitial collagen barriers into hypoxic tumour cores.
Targeted radiofrequency acoustic impulses stimulate carrier magnetoelectric depolarization, cleaving surface covalent bonds to discharge high-concentration chemotherapeutics locally.
Integrated platform specifications
Magnetoelectric nanorobot core
Fabricated under ISO cleanroom standards, each core features a cobalt-ferrite core with barium-titanate shell chemistry engineered for predictable magnetic moment and uniform 120 nm hydrodynamic diameter.
Tri-axial electromagnetic gantry
Configured as eight water-cooled Helmholtz and Maxwell coil pairs, the hardware delivers homogenous field strengths up to 0.5 Tesla with gradient slopes exceeding 2.5 Tesla per meter across standard clinical working volumes.
Real-time navigation algorithms
Proprietary vector controllers compute non-linear fluidic drag equations at 200 Hz, compensating for pulsating vascular velocities to maintain micron-level targeting precision throughout navigation cycles.
Measured translational metrics
120 nm
core size monodispersity
14.2×
tumour tissue accumulation
890 µm
active stroma penetration
<0.02%
off-target systemic toxicity
Access detailed in vitro cytotoxicity data, 3D field coil calibration protocols, and planned translational in vivo milestones established with institutional oncology partners.